Precigen, Inc. (PGEN)
After hours:
| Previous Close | 1.3800 |
| Open | 1.4000 |
| Bid | 1.3900 x 600 |
| Ask | 1.4200 x 600 |
| Day's Range | 1.3900 - 1.4500 |
| 52 Week Range | 0.8400 - 1.8800 |
| Volume | |
| Avg. Volume | 1,007,527 |
| Market Cap | 348.487M |
| Beta (5Y Monthly) | 1.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3900 |
| Earnings Date | May 08, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.00 |
PR NewswirePrecigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company has teamed up with the Recurrent Respiratory Papillomatosis Foundation (RRPF) to launch the first RRP Awareness Day™ on June 11, 2024, a multi-stakeholder event to raise awareness about recurrent respiratory papillomatosis (RRP) and bring together RRP patients and their caregivers to encourage new conne
Insider MonkeyPrecigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript
Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript March 19, 2024 Precigen, Inc. misses on earnings expectations. Reported EPS is $-0.13 EPS, expectations were $-0.08. PGEN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to the […]
- GuruFocus.com
Precigen Inc (PGEN) Reports Full Year 2023 Financial Results
Challenges Persist as Total Revenues Decline by 76.9% Year-Over-Year
